檢索期末考試作業(yè)

1、福建中醫(yī)藥大學(xué)文獻(xiàn)信息檢索綜合考試報(bào)告（臨床各專業(yè)）（2012版）選題題目 高度惡性膽道梗阻支架植入術(shù)的臨床治療 中英文關(guān)鍵詞或主題詞10 中文關(guān)鍵詞 膽道梗阻 支架植入 治療 英文關(guān)鍵詞 Biliary obstruction sents implantation therpy 研究生姓名 庫(kù)雷志 學(xué)號(hào) 2120908001 學(xué)科專業(yè) 影像醫(yī)學(xué)與核醫(yī)學(xué) 導(dǎo)師姓名 馬明平 報(bào)告完成日期2012/11/18 總成績(jī) 一、本課題學(xué)術(shù)論文檢索（包括期刊論文、會(huì)議論文、學(xué)位論文）請(qǐng)按照下列要求逐一回答。50（一）中文醫(yī)學(xué)摘要數(shù)據(jù)庫(kù)（中醫(yī)藥在線、CMCC）數(shù)據(jù)庫(kù)名稱 中醫(yī)藥在線 檢索年限 1949年以后

2、 檢出篇數(shù) 11篇 檢索表達(dá)式 檢索詞 膽道梗阻 治療 列出你認(rèn)為最相關(guān)文獻(xiàn)的題名、作者、出處、摘要。1.中文題名  中西醫(yī)結(jié)合治療重癥膽道感染80例臨床體會(huì)著者  張東第一著者單位  靖江市中醫(yī)院外科 214500第一著者地址  江蘇刊名  深圳中西醫(yī)結(jié)合雜志年份  2001卷  11期  4頁(yè)碼  226-227主題詞  膽道疾病/中西醫(yī)結(jié)合療法中文摘要  目的：觀察中西醫(yī)

3、結(jié)合治療重癥膽道感染的臨床療效。方法：本病特點(diǎn)為肝膽濕熱為主，本組用柴胡、黃芩、雙花、連翹、金錢草、枳殼、郁金、木香、大黃（后下）、風(fēng)化硝，隨癥加減。針刺取日月、期門及膽俞；伴有嚴(yán)重休克配涌泉穴（雙）。中轉(zhuǎn)手術(shù)組：經(jīng)中西醫(yī)結(jié)合治療后癥狀不能控制或癥狀緩解，感染得到控制，但膽道梗阻不能解除，擇期手術(shù)28例。結(jié)果：本組80例，治愈72例，總治愈率90%，死亡8例。結(jié)論：本法療效滿意。2.中文題名  血塞通注射液對(duì)梗阻性黃疸腎損傷的保護(hù)機(jī)制著者  宋少莉, 周斌, 程彥斌, 王宏亮, 湯曉琴第一著者單位  甘肅 蘭州醫(yī)學(xué)院第一醫(yī)院核醫(yī)學(xué)科

4、730000第一著者地址  甘肅刊名  第四軍醫(yī)大學(xué)學(xué)報(bào)年份  2004卷  25期  15頁(yè)碼  1368-1371主題詞  血塞通注射液/藥理學(xué)；黃疸/病因?qū)W；黃疸/并發(fā)癥；膽汁郁積/并發(fā)癥；基因，BCL-2/藥物作用中文摘要  目的:觀察血塞通注射液對(duì)梗阻性黃疸引起的腎損傷的保護(hù)作用。方法:健康日本大耳白兔48只,隨機(jī)分為2組: A組為膽總管結(jié)扎組24只(obstructive jaundice,OJ);B組為膽總管結(jié)扎+血塞通注

5、射液組24只。每組又進(jìn)一步分為4個(gè)亞組。建立膽道梗阻動(dòng)物模型后,在術(shù)后不同時(shí)期取材測(cè)定血清總膽紅素(T-BIL)、血肌苷(Cr)和尿素氮(BUN)值;用免疫組化法檢測(cè)腎組織Bax、Bcl-2的表達(dá)情況。結(jié)果:膽道梗阻后A、B兩組的腎臟均有Bcl-2和Bax蛋白表達(dá),Bax蛋白在梗阻9 d時(shí)達(dá)高峰。Bcl-2蛋白在梗阻21 d達(dá)高峰.凋亡指數(shù)(AI)隨Bax的升高而升高,隨Bcl-2的升高而降低。B組Bax蛋白表達(dá)較同時(shí)相組弱,而Bcl-2蛋白表達(dá)較同時(shí)相組強(qiáng)。B組AI值較A組降低。結(jié)論:血塞通注射液對(duì)梗阻性黃疸腎損傷有保護(hù)作用,其機(jī)制可能是通過(guò)上調(diào)腎組織Bcl-2蛋白表達(dá),下調(diào)腎組織Bax蛋白

6、的表達(dá)來(lái)實(shí)現(xiàn)的。3 中文題名  黃芪對(duì)梗阻性黃疸大鼠肝功能的保護(hù)作用著者  鮑鷹, 馮文明, 費(fèi)卯云, 陳秋強(qiáng), 楊琦, 戴闖第一著者單位  浙江 湖州市第一醫(yī)院肝膽外科研究所 313000第一著者地址  浙江刊名  中國(guó)中西醫(yī)結(jié)合外科雜志年份  2004卷  10期  4頁(yè)碼  278-280主題詞  膽汁郁積/并發(fā)癥；膽汁郁積/病理生理學(xué)；膽汁郁積/中醫(yī)藥療法；黃芪注射液/藥理學(xué)；黃芪注射液/

7、投藥和劑量；注射，腹腔內(nèi)；內(nèi)皮素1/血液；超氧化物歧化酶/血液；丙二醛/血液；天冬氨酸氨基轉(zhuǎn)移酶類/血液；膽紅素/血液；膽汁酸類和鹽類/血液；黃疸，阻塞性/中醫(yī)藥療法；黃疸，阻塞性/病因?qū)W中文摘要  目的:探討黃芪注射液對(duì)實(shí)驗(yàn)性梗阻性黃疸大鼠肝功能的保護(hù)作用及作用機(jī)理。方法:SD大鼠行膽總管結(jié)扎后分別用3 mL黃芪注射液或生理鹽水腹腔注射。術(shù)后測(cè)定血漿內(nèi)皮素(ET-1)、血清超氧化物歧化酶(SOD)、丙二醛(MDA)含量,同時(shí)測(cè)定谷丙轉(zhuǎn)氨酶(AST)、直接膽紅素(DB)和總膽汁酸(TBA)濃度,并對(duì)肝臟行光鏡下病理形態(tài)學(xué)觀察。結(jié)果:血漿ET-1、血清MDA濃度在梗阻10 d

8、即升高,隨膽道梗阻時(shí)間延長(zhǎng)進(jìn)一步升高,SOD在梗阻10 d即下降,同時(shí)伴有血清AST、DB和TBA的升高和肝臟病理形態(tài)學(xué)的進(jìn)行性改變。黃芪治療組ET-1及MDA顯著低于對(duì)照組,而SOD顯著高于對(duì)照組,并能改善肝組織病理形態(tài)。結(jié)論:大鼠梗阻性黃疸時(shí),血漿ET-1水平升高及氧自由基損害可能是肝損傷的原因,黃芪通過(guò)降低ET-1水平、抗氧化作用對(duì)梗阻性黃疸大鼠的肝臟起保護(hù)作用。4 中文題名  黃芪對(duì)膽道梗阻后心肌損傷保護(hù)作用的實(shí)驗(yàn)研究個(gè)人著者  鞏鵬; 王忠裕; 李克軍;第一著者單位  大連醫(yī)科大學(xué)第一臨床學(xué)院 116011第一著者地址

9、60; 遼寧刊名  中國(guó)中西醫(yī)結(jié)合外科雜志年份  2000卷  6期  6頁(yè)碼  409-411中文文摘   目的:觀察膽道梗阻后心肌損傷及黃芪(AM)的保護(hù)作用。方法 :動(dòng)態(tài)觀測(cè)心肌組織丙二醛(MDA)和超氧化物歧化酶(SOD)、血清T-Bil、 TBA、內(nèi)毒素(ET)、腫瘤壞死因子(TNF)含量;取左室心肌行光電鏡檢查,應(yīng)用A BC免疫組化染色法,定位TNF在心肌組織中的表達(dá)和分布。結(jié)果:膽道梗阻后,血清T-Bil、TBA、ET、TNF水平逐漸升高,心肌組織MD

10、A含量逐漸升高,SOD逐漸減少;各AM治療組與同時(shí)相梗阻組比較,血清 ET、TNF、心肌組織MDA含量減少,SOD含量升高;心肌組織MDA含量與血清TNF含量變化呈正相關(guān);光電鏡下可見隨膽道梗阻時(shí)間延長(zhǎng),心肌組織細(xì)胞損害加重,各AM治療組與同時(shí)相梗阻組比較組織細(xì)胞損害減輕。結(jié)論:AM通過(guò)對(duì)抗自由基損傷、內(nèi)毒素血癥、TNF的綜合作用,對(duì)膽道梗阻所致心肌損傷有明顯保護(hù)作用。5中文題名  丹參注射液對(duì)梗阻性黃疸大鼠肝內(nèi)NO、MDA、ET的影響及其意義個(gè)人著者  李小剛; 劉青光; 潘承恩; 馬清涌; 張梅第一著者單位  西安交通大學(xué)第一醫(yī)院

11、麻醉科 710061第一著者地址  陜西刊名  西安醫(yī)科大學(xué)學(xué)報(bào)年份  2002卷  23期  2頁(yè)碼  158-161中文文摘  目的:探討丹參注射液對(duì)梗阻性黃疸(Obstructive jaundice,OJ)大鼠肝組織中一氧化氮(NO)、丙二醛(MDA)、內(nèi)皮素(ET)的影響及其意義。方法:采用雙重結(jié)扎切斷大鼠膽總管造成OJ模型,分別給大鼠腹腔注射生理鹽水(模型組)和丹參注射液(治療組), 各組于術(shù)后7d和14d觀察肝組織勻漿NO2-+NO 3-、M

12、DA、ET含量,肝功能及肝組織形態(tài)改變。結(jié)果:膽道梗阻7d和14d后大鼠肝組織中NO2-+NO3-、MDA含量較正常鼠明顯增加,兩者不隨梗阻時(shí)間延長(zhǎng)而升高;肝組織中ET含量亦明顯增高,且隨時(shí)間延長(zhǎng)而增高。丹參治療組大鼠肝組織中NO2-+NO3-與模型組無(wú)差異,而MDA和ET含量明顯低于模型組,血漿ALT、AST明顯降低,肝組織損傷減輕。結(jié)論:丹參注射液可降低 OJ大鼠肝內(nèi)MDA、ET含量,從而發(fā)揮肝臟保護(hù)作用。數(shù)據(jù)庫(kù)名稱 CMCC 檢索年限 2007-2012 檢出篇數(shù) 15篇 檢索表達(dá)式 檢索條件：膽道梗阻/FLD=關(guān)鍵詞,題名,外文題名,摘要 AND 支架植入/FLD=關(guān)鍵詞,題名,外文題

13、名,摘要 AND #年>=2007 AND #年<=2012 AND #核心期刊=Y AND #有無(wú)摘要=Y列出你認(rèn)為最相關(guān)文獻(xiàn)的題名、作者、出處、摘要。1 題名：支架植入治療惡性膽道梗阻217例分析作者：陳佐會(huì), 黃強(qiáng)單位：湖北 恩施湖北民族學(xué)院附屬醫(yī)院肝膽外科 445000出處：廣東醫(yī)學(xué) 2010V31N21 2835-2836關(guān)鍵詞：惡性膽道梗阻, 支架, 介入摘要：目的:探討植入支架姑息性治療惡性膽道梗阻的治療效果。方法:總結(jié)分析近10年來(lái),采用支架植入方法治療惡性膽道梗阻成功的217例病例資料。結(jié)果:本組247例,經(jīng)一次或多次操作,成功植入支架217例,共植入支架278只

14、,成功率為87.85%。術(shù)后當(dāng)天患者癥狀及體征得到改善,48h后黃疸癥狀減輕,且無(wú)嚴(yán)重并發(fā)癥發(fā)生。結(jié)論:支架植入治療膽道惡性梗阻成功率高,解除梗阻效果明顯,能延長(zhǎng)患者生存時(shí)間,減輕生存期間痛苦,是一種安全有效的治療方法。2題名：經(jīng)皮肝穿刺膽道內(nèi)支架植入治療惡性膽道梗阻術(shù)后并發(fā)癥的護(hù)理外文題名：Nursing of patients with postoperative complications following percutaneous transhepatic cholangiographic drainage and biliary tract stent implantation f

15、or malignant obstructive jaundice作者：張希, 唐芙蓉單位：湖南 株洲市一醫(yī)院肝膽外科 412000出處：中華護(hù)理雜志 2009V44N8 693-694關(guān)鍵詞：膽道腫瘤, 膽汁淤積, 穿刺抽液術(shù), 支架, 手術(shù)后并發(fā)癥, 護(hù)理摘要：總結(jié)了惡性膽道梗阻經(jīng)皮肝穿刺膽道內(nèi)支架植入術(shù)后并發(fā)癥的觀察和護(hù)理。32例患者中,8例出現(xiàn)術(shù)后并發(fā)癥,包括膽道出血2例、膽道感染4例、氣胸1例、膽漏1例。經(jīng)過(guò)周密觀察和護(hù)理,患者安全度過(guò)圍手術(shù)期,生存質(zhì)量明顯改善。3題名：惡性膽道梗阻ERCP表現(xiàn)及膽道內(nèi)支架治療外文題名：The ERCP manifestation and treat

16、ment with endoscopic biliary stenting in Malignant Biliary Obstruction作者：吳發(fā)喬, 高燕, 李欠云單位：浙江 溫嶺市第三人民醫(yī)院放射科 317523出處：醫(yī)學(xué)影像學(xué)雜志 2008V18N10 1163-1165關(guān)鍵詞：內(nèi)鏡, 膽道內(nèi)支架, 惡性膽道梗阻, 介入性治療摘要：目的:評(píng)價(jià)ERCP在惡性膽道梗阻診斷及膽道內(nèi)支架治療的價(jià)值。方法:回顧性分析19例惡性膽道梗阻ERCP表現(xiàn)和內(nèi)支架植入情況。結(jié)果:19例惡性膽道梗阻ERCP表現(xiàn)直接征象:膽管截?cái)嗾?例、不規(guī)則偏心性或向心性狹窄9例、不規(guī)則充盈缺損1例。間接征象:梗阻近端膽

17、總管中、重度擴(kuò)張,肝內(nèi)膽管擴(kuò)張,呈軟藤征;膽囊增大;胰管擴(kuò)張等。19例共植入支架22個(gè),一次操作成功率95.65%,低位梗阻減黃有效率達(dá)92.85%,高位梗阻減黃有效率達(dá)80.00%。結(jié)論:ERCP對(duì)于膽道梗阻定位、定性診斷有很大價(jià)值,膽道內(nèi)支架引流術(shù)可以作為惡性膽道梗阻姑息性治療的首選方法。4題名：介入法支架植入術(shù)治療惡性膽道梗阻外文題名：The Interventional Treatment of Malignant Biliary Obstruction by Implantation Stend作者：王彥華, 王松, 李子祥, 孫成建, 孫曉瑋, 仇紅單位：山東 青島大學(xué)醫(yī)學(xué)院介入放

18、射科 266003出處：腫瘤防治研究 2007V34N2 149-150資助：國(guó)家自然科學(xué)基金資助項(xiàng)目 (30070895)關(guān)鍵詞：支架, 介入, 惡性膽道梗阻摘要：目的:探討植入支架術(shù)治療惡性膽道梗阻的療效及其并發(fā)癥。方法:46例惡性膽道梗阻的患者在DSA的引導(dǎo)下接受經(jīng)皮肝穿刺膽道支架植入術(shù)。結(jié)果:46例放置了膽道支架,共用支架50只,其中13例為雙支架,4例術(shù)后行經(jīng)肝動(dòng)脈化療和(或)栓塞。減黃總有效率達(dá)85.4%。支架阻塞5例。主要并發(fā)癥:敗血癥3例,肝功損害6例。結(jié)論:支架植入術(shù)成功率高,減黃療效好,是姑息性治療惡性膽道梗阻安全簡(jiǎn)單的治療方法。5題名：經(jīng)皮肝穿刺膽道支架植入后再狹窄分析及

19、介入治療外文題名：The Cause and Treatment of Restenosis after Percutaneous Transhepatic Biliary Stent Placement作者：孫華, 董永安, 李東輝, 季芳英, 吳文中單位：陜西 西安陜西省人民醫(yī)院介入放射科 710068出處：實(shí)用放射學(xué)雜志 2007V23N8 1093-1095關(guān)鍵詞：膽道, 惡性梗阻, 支架術(shù)后再狹窄, 介入放射學(xué)摘要：目的:探討惡性膽道梗阻性黃疸經(jīng)皮肝穿刺膽道支架置放術(shù)后支架再狹窄原因及介入治療。方法:20例膽道支架再狹窄患者,根據(jù)術(shù)后引流量及黃疸消退情況,于2周,1個(gè)月,2個(gè)月,3個(gè)

20、月復(fù)查肝功、血、尿、糞及B超、CT、經(jīng)引流管膽道造影,確認(rèn)支架再狹窄性質(zhì)、部位后,利用外置引流管途徑行介入再通治療。支架均為國(guó)產(chǎn)普通鎳鈦合金膽道支架,直徑10mm,長(zhǎng)度40-80mm。結(jié)果:20例支架再狹窄中,9例為腫瘤浸潤(rùn)壓迫所致,3例為支架上端成角致阻塞,4例為膽泥及食物殘?jiān)蜿惻f性凝血塊阻塞支架,2例為膽管炎性狹窄,2例為肉芽組織增生引起阻塞。全部再狹窄病例經(jīng)引流管抽吸、藥物灌注、沖洗、導(dǎo)管導(dǎo)絲疏通、球囊擴(kuò)張、支架再植入予以復(fù)通,生存期超過(guò)6個(gè)月。結(jié)論:經(jīng)皮肝穿刺膽道支架植入術(shù)治療惡性膽道梗阻,術(shù)后支架再狹窄率仍較高,應(yīng)引起重視。（二）中文全文數(shù)據(jù)庫(kù)（萬(wàn)方數(shù)據(jù)庫(kù)、維普數(shù)據(jù)庫(kù)和CNKI，分

21、別填寫各數(shù)據(jù)庫(kù)命中結(jié)果數(shù)；列出你認(rèn)為符合條件，但又不重復(fù)的2-3條文獻(xiàn)題錄或文摘。數(shù)據(jù)庫(kù)名稱 萬(wàn)方數(shù)據(jù)庫(kù) 檢索年限 2007-2012 檢出篇數(shù) 189篇 檢索表達(dá)式 title:膽道梗阻 keyword:支架植入 date:2007-2012 符合條件，但又不重復(fù)的2-3條論文的文摘（三大全文數(shù)據(jù)庫(kù)粘貼出的文獻(xiàn)不要重復(fù)）1. 黃曉東,范彥,張姮等.內(nèi)鏡下膽道支架置入術(shù)治療惡性膽道梗阻122例J.世界華人消化雜志,2008,16(28):3234-3237.2. 王建國(guó),張堅(jiān),劉福忠,尚錦云. 膽道支架植入加化療灌注治療惡性膽道梗阻J. 當(dāng)代醫(yī)學(xué),2009,(17).3.  陳欽壽,

22、 葉觀瑞, 車斯堯, 梁日光, 潘思波, 黃燕金, 梁永任, 廖均平, 何龍光, CHEN Qinshou, YE Guanrui, CHE Siyao, LIANG Riguang, PAN Sibo, HUANG Yanjin, LIANG Yongren, LIAO Junping, HE Longguang - 臨床醫(yī)學(xué) 2009年4期數(shù)據(jù)庫(kù)名稱 維普數(shù)據(jù)庫(kù) 檢索年限 2007-2012 檢出篇數(shù) 16 篇 檢索表達(dá)式 關(guān)鍵詞=膽道梗阻 與 關(guān)鍵詞=支架置入 與 時(shí)間=2007-2012 與 范圍=全部期刊 1. 戴真煜,姚立正,李文會(huì),董從松,朱軍. 經(jīng)皮膽道支架聯(lián)合支架旁(125)

23、粒子條植入治療惡性膽道梗阻J. 介入放射學(xué)雜志,2011,(92. 吳上覺. 膽道支架對(duì)惡性膽道梗阻的治療研究J. 臨床醫(yī)藥實(shí)踐雜志,2008,(18).3. 李啟民,喬惠萍,穆永旭,何俊峰. 介入方法治療惡性梗阻性黃疸的體會(huì)J. 中外醫(yī)療,2009,(32).數(shù)據(jù)庫(kù)名稱 CNKI數(shù)據(jù)庫(kù) 檢索年限 2007-2012 檢出篇數(shù) 76 篇 檢索表達(dá)式 ( (主題=中英文擴(kuò)展(支架植入術(shù)) 并且 主題=中英文擴(kuò)展(膽道梗阻)(精確匹配)1. 周靜,柏愚,鄒多武.膽管雙金屬支架置入術(shù)后并發(fā)膽道梗阻合并感染一例.中華消化內(nèi)鏡雜志,2011,28(12);716-7162.查勇,寸英麗,黃云超.經(jīng)皮金屬

24、支架置入治療惡性高位膽道梗阻.第三軍醫(yī)大學(xué)學(xué)報(bào),2009,(20);2034-20343. 王紹金,田國(guó)利,康麗.惡性膽道梗阻應(yīng)用內(nèi)鏡置放膽道支架治療分析.中國(guó)醫(yī)藥指南,2011,9(32);133-134（三）外文醫(yī)學(xué)文獻(xiàn)檢索工具PubMed、 ScienceDirect、FMJS，并回答下列問(wèn)題：數(shù)據(jù)庫(kù)名稱 PuMed 檢索年限 2007-2012 ；檢出文獻(xiàn)題錄數(shù) 109 篇 中英文檢索詞 膽道梗阻支架植入 Biliary obstruction stents implantation 檢索表達(dá)式 BiliaryAll Fields AND obstructionAll Fie

25、lds AND ("stents"MeSH Terms OR "stents"All Fields) AND ("embryo implantation"MeSH Terms OR ("embryo"All Fields AND "implantation"All Fields) OR "embryo implantation"All Fields OR "implantation"All Fields) 1 列出你認(rèn)為最相關(guān)的篇文獻(xiàn)的題錄，并復(fù)制粘貼該篇

26、文獻(xiàn)標(biāo)引的全部主題詞。1 1: Kim DU, Kang DH, Kim GH, Song GA, Kim CW, Kim S, Jang AL. Bilateral biliarydrainage for malignant hilar obstruction using the 'stent-in-stent' method with aY-stent: efficacy and complications. Eur J Gastroenterol Hepatol. 2012 Sep 26.Epub ahead of print PubMed PMID: 23022984M

27、eSH Terms· Adult · Aged · Aged, 80 and over · Bile Duct Neoplasms/radiography · Bile Duct Neoplasms/surgery* · Chi-Square Distribution · Cholangiography · Cholestasis/radiography · Cholestasis/surgery* · Contrast Media · Female · Humans

28、83; Infection/epidemiology · Infection/radiography* · Logistic Models · Male · Metals · Middle Aged · Postoperative Complications/epidemiology · Postoperative Complications/radiography* · Prosthesis Implantation · Radiography, Interventional · Retros

29、pective Studies · Risk Factors · Stents/adverse effects*2 1: Dumonceau JM, Tringali A, Blero D, Devière J, Laugiers R, Heresbach D,Costamagna G; European Society of Gastrointestinal Endoscopy. Biliary stenting:indications, choice of stents and results: European Society of Gastrointest

30、inalEndoscopy (ESGE) clinical guideline. Endoscopy. 2012 Mar;44(3):277-98. Epub 2012 Feb 1. PubMed PMID: 22297801.MeSH Terms· Biliary Tract Diseases/therapy* · Biliary Tract Neoplasms/complications · Cholecystectomy/adverse effects · Cholestasis/etiology · Cholestasis/therap

31、y · Constriction, Pathologic/etiology · Constriction, Pathologic/therapy · Drainage · Endoscopy, Digestive System · Humans · Liver Transplantation/adverse effects · Palliative Care* · Pancreatitis, Chronic/complications · Prosthesis Failure · Prosthe

32、sis Implantation/standards · Stents/adverse effects · Stents/standards*2、這2篇文獻(xiàn)是否有可擴(kuò)展或鏈接的信息？請(qǐng)截圖，并簡(jiǎn)述信息的內(nèi)容LinkOut - more resources PMC Free 部分全文 Early Infectious Complications of Percutaneous Metallic Stent Insertion for Malignant Biliary Obstruction· Yu Li Sol1, · Chang Won Kim1, &

33、#183; Ung Bae Jeon1, · Nam Kyung Lee1, · Suk Kim1, · Dae Hwan Kang2 and · Gwang Ha Kim2+ Author Affiliations1. 1Department of Radiology, College of Medicine, Medical Research Institute, Pusan National University Hospital, 1-10, Ami-Dong, Seo-Gu, Busan 602-739, Republic of Korea.

34、2. 2Department of Internal Medicine, College of Medicine, Pusan National University Hospital, Busan, Republic of Korea. Next SectionAbstractOBJECTIVE. This study was designed to evaluate predisposing factors for early infectious complications after percutaneous metallic biliary stent insertion in pa

35、tients with malignant biliary obstruction. MATERIALS AND METHODS. From August 1999 to June 2008, 215 consecutively registered patients with inoperable malignant biliary obstruction were treated with percutaneous placement of a metallic stent. The incidence of early infectious complications was evalu

36、ated. Sex, age, level of obstruction, type and number of stents, and stent position (across or above the main duodenal papilla) were retrospectively reviewed. The findings in patients with early infectious complications were compared with those in patients without early infectious complications. RES

37、ULTS. Infectious complications occurred within 30 days after stent placement in 14 of 215 (6.5%) patients. Univariate analysis showed a significant difference between the two groups with respect to nontranspapillary stent placement (p = 0.003). In the multiple logistic regression analysis, age, sex,

38、 level of obstruction, and type and number of stents were negatively associated with the development of early infectious complications (p > 0.05). CONCLUSION. Our study data showed that stent placement across the main duodenal papilla seemed to prevent early infectious complications after percuta

39、neous metallic .3、你能否獲取該數(shù)據(jù)庫(kù)命中文獻(xiàn)中的一篇全文？請(qǐng)拷貝粘貼全文的PDF首頁(yè)。答；能數(shù)據(jù)庫(kù)名稱 FMJS 檢索年限 2007-2012 ；檢出文獻(xiàn)題錄數(shù) 94篇 中英文檢索詞 膽道梗阻支架植入 Biliary obstruction stents implantation 檢索表達(dá)式 自由詞全部=Biliary obstruction stents implantation 1、列出你認(rèn)為最相關(guān)的篇文獻(xiàn)的題錄，并復(fù)制粘貼該篇文獻(xiàn)標(biāo)引的全部主題詞。1題名：Biliary stents.作者：Meyenberger Ch;Fantin AC ;出處：Ther Umsch.

40、2003V60N4:225-32文獻(xiàn)類型：Comparative Study;English Abstract;Journal Article;Review;ISSN：0040-5930 (Print)0040-5930 (Linking)語(yǔ)種：ger出版國(guó)：Switzerland摘要：PURPOSE: Retrospective analysis of our results with metallic stent placement for malignant biliary strictures. We sought to determine parameters that influe

41、nce stent patency. METHODS: A total of 95 Wallstents were implanted in 65 patients (38 men, 27 women; mean age, 65.1 years) with malignant biliary obstruction. Serum bilirubin levels were assessed in 48 patients; the mean value prior to intervention was 15.0 mg/dl. RESULTS: In 12 patients (21%) comp

42、lications occurred as a result of percutaneous transhepatic drainage. Stent implantation was complicated in 13 patients, but was possible in all patients. A significant decrease in bilirubin level was seen in 83.3% of patients following stent implantation. Approximately 30% of patients developed rec

43、urrent jaundice after a mean 97.1 days. In 9 patients (15%) the recurrent jaundice was caused by stent occlusion due to tumor growth. The mean follow-up was 141.8 days, the mean survival 118.7 days. Patients with cholangiocarcinomas and gallbladder carcinomas had the best results. Worse results were

44、 seen in patients with pancreatic tumors and with lymph node metastases of colon and gastric cancers. CONCLUSIONS: The main predictive factors for occlusion rate and survival are the type of primary tumor, tumor stage, the decrease in bilirubin level, and the general condition of the patient.主題詞MeSH

45、Bile Duct Neoplasms/complications 【膽管腫瘤/并發(fā)癥】*Bile Ducts 【膽管】Bile Ducts, Intrahepatic 【膽管, 肝內(nèi)】Cholangiocarcinoma/complications 【膽管上皮癌/并發(fā)癥】Cholangitis, Sclerosing/complications 【膽管炎, 硬化性/并發(fā)癥】Cholecystectomy/adverse effects 【膽囊切除術(shù)/副作用】Cholelithiasis/complications 【膽結(jié)石/并發(fā)癥】Cholestasis/etiology/surgery/*

46、therapy 【膽汁淤積/病因?qū)W/外科學(xué)/治療】Common Bile Duct 【膽總管】Constriction, Pathologic/etiology/therapy 【縮窄, 病理性/病因?qū)W/治療】Endoscopy 【內(nèi)窺鏡檢查】Humans 【人類】Liver Neoplasms/complications/secondary 【肝腫瘤/并發(fā)癥/繼發(fā)性】Liver Transplantation/adverse effects 【肝移植/副作用】Lymphatic Metastasis 【淋巴轉(zhuǎn)移】Metals 【金屬】*Pancreatic Ducts 【胰腺管】Pancre

47、atic Neoplasms/therapy 【胰腺腫瘤/治療】2題名：Biliary stents.作者：Meyenberger Ch;Fantin AC ;出處：Ther Umsch.2003V60N4:225-32文獻(xiàn)類型：Comparative Study;English Abstract;Journal Article;Review;ISSN：0040-5930 (Print)0040-5930 (Linking)語(yǔ)種：ger出版國(guó)：Switzerland摘要：Endoscopically implantable stents are today the mainstay for t

48、herapy of biliary stenoses. It is important to know if a benign or a malignant stenosis is the cause of the biliary obstruction. Generally benign stenoses are treated with plastic-stents whereas malignant stenoses are managed by implantation of a metallic stent. The main indications for plastic sten

49、ts are postoperative strictures in the biliary tree for example, after biliary tract surgery or liver transplantation, primary sclerosing cholangitis and postoperative biliary leakage. Metallic stents are implanted in palliative circumstances like in stenosing cholangiocarcinoma or in situations whe

50、re a hepatic metastasis exerts an extrinsic compression on the biliary tract with consecutive cholestasis. The materials used for manufacturing both stent types are biologically inert and thus biocompatible. A current poorly resolved problem is the occlusion of the stent lumen (by sludge, bacterial

51、degradation products etc.) which occurs in both stent types with time. These problems lead to stentocclusion around three to six months after implantation and necessitate endoscopical re-interventions in order to overcome the occlusion. The patency rate for metallic stents is better than for plastic

52、 ones. The endoscopic stenttherapy is equivalent to surgical therapy (Intestinal bypass-procedures.主題詞MeSHBile Duct Neoplasms/*complications 【膽管腫瘤/并發(fā)癥】Cholangiocarcinoma/*complications 【膽管上皮癌/并發(fā)癥】Cholangiopancreatography, Endoscopic Retrograde/adverse effects 【胰膽管造影術(shù), 內(nèi)窺鏡逆行/副作用】Cholangiopancreatogra

53、phy, Magnetic Resonance 【胰膽管造影術(shù), 磁共振】Cholestasis/*etiology/surgery/*therapy 【膽汁淤積/病因?qū)W/外科學(xué)/治療】Constriction, Pathologic/etiology/therapy 【縮窄, 病理性/病因?qū)W/治療】Humans 【人類】Jaundice, Obstructive/etiology/surgery/*therapy 【黃疸, 阻塞性/病因?qū)W/外科學(xué)/治療】Metals 【金屬】*Stents/adverse effects 【支架/副作用】2、這2篇文獻(xiàn)是否有可擴(kuò)展或鏈接的信息？請(qǐng)截圖，并簡(jiǎn)述信息的內(nèi)容。答；有1.相關(guān)鏈接：Google 引文 PubMed相關(guān)文獻(xiàn) Expandable metal stents for malignant hilar biliary obstructionMost patients with malignant hilar stenoses are candidates for palliation. For this purpose, biliary drainage plays a major role in improving liver function and manag